Publicação: Effect of a nanostructured dendrimer-naloxonazine complex on endogenous opioid peptides mu(1) receptor-mediated post-ictal antinociception
Carregando...
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Elsevier B.V.
Tipo
Artigo
Direito de acesso
Acesso restrito
Resumo
The aim of this study was to investigate the capacity of the host dendrimer DAB-Am-16 as a drug carrier to reduce the time required for the encapsulated naloxonaxine to establish an irreversible covalent bond with mu(1)-opioid receptor (resulting in a pharmacologically selective effect). The efficacy of dendrimer-naloxonazine nanocomplex (DNC) was studied in antinociception induced by convulsions elicited by intraperitoneal (IP) administration of pentylenetetrazole, and analgesia was measured by the tail-flick test. We found that animals showed increased tail-flick latencies following convulsions. Furthermore, acute pre-treatment (10 minutes) with DNC, but not with naloxonazine alone, antagonized post-ictal analgesia in comparison with control pre-treatment. However, naloxonazine treatment 24 hours before PTZ decreased post-ictal antinociception, but DNC failed to antagonize tonic-clonic seizure-induced analgesia. In addition, according to Racine's index of seizure severity, naloxonazine, DAB-Am-16 dendrimer or DNC did not influence seizure severity when administered either 10 minutes or 24 hours before PTZ.From the Clinical Editor: This study characterizes the effect of a dendrimer-naloxonazine complex on mu(1) receptor-mediated post-ictal antinociception in an animal model of seizure disorder. (C) 2011 Elsevier B.V. All rights reserved.
Descrição
Palavras-chave
DAB-Am-16 Dendrimer, GABA-A receptor, mu(1)-opioid receptor, Post-ictal analgesia, nanostructured materials
Idioma
Inglês
Como citar
Nanomedicine-nanotechnology Biology and Medicine. Amsterdam: Elsevier B.V., v. 7, n. 6, p. 871-880, 2011.
